What's in Allergopharma GmbH & Co. KG's pipeline?

Allergopharma GmbH & Co. KG has 14 drugs in our index: 2 marketed, 0 filed, 9 in Phase 3, 3 in Phase 2, 0 in Phase 1.

Which companies overlap with Allergopharma GmbH & Co. KG's portfolio?

Top competitors by shared drug class: ALK-Abelló A/S, Anergis, Beijing Tongren Hospital, HAL Allergy, Johns Hopkins University.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/allergopharma-gmbh-co-kg.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Allergopharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Allergopharma GmbH & Co. KG pipeline: 2 marketed, 0 filed, 9 Phase 3, 3 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 9 Phase 3 3 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
wasp venom	wasp venom	marketed	Allergen immunotherapy		Immunology / Allergy
House dust mite Novo Helisen Depot	House dust mite Novo Helisen Depot	marketed	Allergen immunotherapy		Immunology / Allergy
Birch pollen allergoid	Birch pollen allergoid	phase 3	Allergen immunotherapy (allergoid)	Birch pollen allergens (Bet v 1 and related epitopes)	Immunology / Allergy
Recombinant birch pollen	Recombinant birch pollen	phase 3	Allergen immunotherapy	Birch pollen allergens (Bet v 1 and related epitopes)	Immunology / Allergy
Grass pollen formulation	Grass pollen formulation	phase 3	Allergen immunotherapy (AIT)		Immunology / Allergy
Grass pollen specific immunotherapy	Grass pollen specific immunotherapy	phase 3	Allergen immunotherapy		Immunology
Recombinant grass pollen	Recombinant grass pollen	phase 3	Allergen immunotherapy	Grass pollen allergens (recombinant)	Immunology / Allergy
recombinant birch pollen allergen	recombinant birch pollen allergen	phase 3	Allergen immunotherapy	Birch pollen allergens (Bet v 1 and related epitopes)	Immunology / Allergy
Acaroid	Acaroid	phase 3			Other
AL0704rP	AL0704rP	phase 3	Allergen immunotherapy		Immunology / Allergy
Allerslit forte	Allerslit forte	phase 3	Allergen immunotherapy		Immunology / Allergy

Therapeutic area mix

Immunology / Allergy · 9
Immunology · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

ALK-Abelló A/S · 1 shared drug class
Anergis · 1 shared drug class
Beijing Tongren Hospital · 1 shared drug class
HAL Allergy · 1 shared drug class
Johns Hopkins University · 1 shared drug class
Laboratorios Leti, S.L. · 1 shared drug class
Medical University of Silesia · 1 shared drug class
National Taiwan University Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Allergopharma GmbH & Co. KG:

Cite this brief

Drug Landscape (2026). Allergopharma GmbH & Co. KG — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/allergopharma-gmbh-co-kg. Accessed 2026-05-16.